Abstract
Pharmaceutical industry funding has transformed much grassroots community activism on health into corporate-sponsored advocacy. This critical commentary outlines recent evidence about industry funding of patient advocacy groups, offers a commentary on the history of grassroots activism appearing in this issue of the journal, and calls for greater scrutiny of the impacts and ethics of such sponsorship.
| Original language | English |
|---|---|
| Pages (from-to) | 61-63 |
| Number of pages | 3 |
| Journal | Journal of Bioethical Inquiry |
| Volume | 17 |
| Issue number | 1 |
| Early online date | 24 Mar 2020 |
| DOIs |
|
| Publication status | Published - Mar 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Commentary: The Voice of the People, Funded Now by Your Friendly Pharmaceutical Company'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver